Herceptin resistance in HER2-moderately expressed breast cancer
<p>HER2 overexpression occurs in approximately 15-20% of all breast cancers and is associated with poor prognosis. The development of Herceptin, a monoclonal antibody against HER2, has been significant in prolonging survival of these patients. Herceptin is less efficient in patients who do not...
| المؤلفون الرئيسيون: | , |
|---|---|
| مؤلفون آخرون: | |
| التنسيق: | أطروحة |
| اللغة: | English |
| منشور في: |
2012
|
| الموضوعات: |